Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is a male or female at least 18 years of age~* Participant is HIV positive~* Participant is naïve to antiretroviral therapy (ART) and has not received any ART~Exclusion Criteria:~* Participant has received approved or experimental antiretroviral agents in the past~* Participant has been treated for a viral infection other than HIV such as hepatitis B virus infection with an agent that is active against HIV including but not limited to adefovir or lamivudine (= 7 days total)~* Participant has documented resistance to tenofovir, emtricitabine, and/or efavirenz~* Participant has used another experimental HIV-integrase inhibitor~* Participant has a current (active) diagnosis of acute hepatitis due to any cause~* Participants with chronic hepatitis including chronic hepatitis B and/or C may enter the study as long as they have stable liver function tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-0518 400 mg b.i.d. (Type: EXPERIMENTAL): MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
- Efavirenz 600 mg q.h.s. (Type: ACTIVE_COMPARATOR): Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).